These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34871146)

  • 1. Changes in KPC-producing
    Boattini M; Bianco G; Comini S; Iannaccone M; Casale R; Charrier L; Cavallo R; Costa C
    Infect Dis (Lond); 2022 Apr; 54(4):311-313. PubMed ID: 34871146
    [No Abstract]   [Full Text] [Related]  

  • 2. Phenotypic and genotypic analysis of KPC-51 and KPC-52, two novel KPC-2 variants conferring resistance to ceftazidime/avibactam in the KPC-producing Klebsiella pneumoniae ST11 clone background.
    Sun L; Chen W; Li H; Li L; Zou X; Zhao J; Lu B; Li B; Wang C; Li H; Liu Y; Cao B
    J Antimicrob Chemother; 2020 Oct; 75(10):3072-3074. PubMed ID: 32719857
    [No Abstract]   [Full Text] [Related]  

  • 3. Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series.
    van Asten SAV; Boattini M; Kraakman MEM; Bianco G; Iannaccone M; Costa C; Cavallo R; Bernards AT
    J Infect Chemother; 2021 May; 27(5):778-780. PubMed ID: 33558042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment.
    Galani I; Karaiskos I; Angelidis E; Papoutsaki V; Galani L; Souli M; Antoniadou A; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 2021 Jan; 40(1):219-224. PubMed ID: 32729059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bloodstream infection by two subpopulations of Klebsiella pneumoniae ST1685 carrying KPC-33 or KPC-14 following ceftazidime/avibactam treatment: considerations regarding acquired heteroresistance and choice of carbapenemase detection assay.
    Bianco G; Boattini M; Iannaccone M; Cavallo R; Costa C
    J Antimicrob Chemother; 2020 Oct; 75(10):3075-3076. PubMed ID: 32676660
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam from ST11 Carbapenem-Resistant
    Wu Y; Yang X; Liu C; Zhang Y; Cheung YC; Wai Chi Chan E; Chen S; Zhang R
    Microbiol Spectr; 2022 Apr; 10(2):e0265521. PubMed ID: 35416703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity.
    Poirel L; Vuillemin X; Juhas M; Masseron A; Bechtel-Grosch U; Tiziani S; Mancini S; Nordmann P
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32457107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate.
    Jousset AB; Oueslati S; Emeraud C; Bonnin RA; Dortet L; Iorga BI; Naas T
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0116021. PubMed ID: 34606331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
    [No Abstract]   [Full Text] [Related]  

  • 11. Isolation of a Ceftazidime-Avibactam-Resistant
    Shen S; Shi Q; Han R; Guo Y; Yang Y; Wu S; Yin D; Hu F
    Microbiol Spectr; 2022 Feb; 10(1):e0184021. PubMed ID: 35080422
    [No Abstract]   [Full Text] [Related]  

  • 12. Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments.
    Gaibani P; Bovo F; Bussini L; Lazzarotto T; Amadesi S; Bartoletti M; Viale P; Ambretti S
    J Antimicrob Chemother; 2022 May; 77(6):1570-1577. PubMed ID: 35373297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.
    Göttig S; Frank D; Mungo E; Nolte A; Hogardt M; Besier S; Wichelhaus TA
    J Antimicrob Chemother; 2019 Nov; 74(11):3211-3216. PubMed ID: 31365094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient.
    Gaibani P; Gatti M; Rinaldi M; Crovara Pesce C; Lazzarotto T; Giannella M; Lombardo D; Amadesi S; Viale P; Pea F; Ambretti S
    Int J Infect Dis; 2021 Dec; 113():213-217. PubMed ID: 34656787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
    Papadimitriou-Olivgeris M; Bartzavali C; Lambropoulou A; Solomou A; Tsiata E; Anastassiou ED; Fligou F; Marangos M; Spiliopoulou I; Christofidou M
    J Antimicrob Chemother; 2019 Jul; 74(7):2051-2054. PubMed ID: 31002313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.
    Di Pilato V; Aiezza N; Viaggi V; Antonelli A; Principe L; Giani T; Luzzaro F; Rossolini GM
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33106265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam.
    Guzmán-Puche J; Pérez-Nadales E; Pérez-Vázquez M; Causse M; Gracia-Ahufinger I; Mendez-Natera A; Allalou-Ruiz Y; Elías C; Oteo-Iglesias J; Torre-Cisneros J; Martínez-Martínez L
    Int J Antimicrob Agents; 2022 Feb; 59(2):106524. PubMed ID: 35038557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KPC Beta-Lactamases Are Permissive to Insertions and Deletions Conferring Substrate Spectrum Modifications and Resistance to Ceftazidime-Avibactam.
    Hobson CA; Bonacorsi S; Jacquier H; Choudhury A; Magnan M; Cointe A; Bercot B; Tenaillon O; Birgy A
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 33020157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.
    Gaibani P; Campoli C; Lewis RE; Volpe SL; Scaltriti E; Giannella M; Pongolini S; Berlingeri A; Cristini F; Bartoletti M; Tedeschi S; Ambretti S
    J Antimicrob Chemother; 2018 Jun; 73(6):1525-1529. PubMed ID: 29566151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.
    Yasmin M; Fouts DE; Jacobs MR; Haydar H; Marshall SH; White R; D'Souza R; Lodise TP; Rhoads DD; Hujer AM; Rojas LJ; Hoyen C; Perez F; Edwards A; Bonomo RA
    Clin Infect Dis; 2020 Aug; 71(4):1095-1098. PubMed ID: 31802119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.